Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Friday, 5 January 2018

IBA SA : IBA signs contract for additional treatment capacity at Latin America's first proton therapy center in Argentina

IBA SA    

Published: 07:15 CET 05-01-2018 /GlobeNewswire /Source: IBA SA / : IBAB /ISIN: BE0003766806


IBA signs contract for additional treatment capacity at Latin America's
first proton therapy center in Argentina

 

Contract for additional gantry treatment room for Proteus®PLUS solution,
already under construction

 

Louvain-la-Neuve, Belgium, January 5, 2018 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has signed a new contract with INVAP for an additional gantry treatment room at the CNEA - UBA New Technologies Cancer Treatment Center to be installed in Buenos Aires, Argentina, in a collaboration between CNEA, UBA (University of Buenos Aires), and other institutions. This new equipment order has been booked in 2017 and is worth between EUR 10 and 15 million to IBA, including a multi-year service agreement. IBA expects to receive a down payment for this new contract in the coming weeks.

 

In September 2015, IBA signed its first collaboration contract with INVAP and CNEA (Comisión Nacional de Energia Atómica) to install the first proton therapy system in Latin America. The Proteus®PLUS* solution will now include two gantry treatment rooms with next generation Pencil Beam Scanning capability and integrated Cone Beam CT as well as a dedicated research room. The center will also benefit from the most advanced room matching available, enabling maximum flexibility of room scheduling and allowing for a minimum 30% reduction in commissioning time therefore giving maximum flexibility for patient treatment.

 

Olivier Legrain, Chief Executive Officer of IBA commented: "The extension of our collaboration with INVAP endorses IBA's position as the trusted partner for the development and delivery of proton therapy treatment facilities around the world. We are delighted to expand on our original agreement to install the first proton therapy system in Latin America as it will give improved access to this life changing treatment to more patients globally."

 

Alberto Lamagna, Vice President of CNEA, commented: "By bringing an innovative new cancer center closer to the people that need it, doctors have a greater variety of methods to treat cancer. Proton therapy is used today to treat a wide range of cancers and it can be used where treatment options were previously limited. Proton therapy has the potential to improve treatment results and decrease the risk of secondary effects or long-term complications, leading to improved patients' quality of life.

 

"This collaboration between CNEA, INVAP and IBA, the global leader in proton therapy, is significant and an important milestone for our future long-term partnerships with these organizations to benefit more cancer patients in Argentina and Latin America."

 

 

Notes to Editors

 

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

 

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

 

*Proteus®PLUS is a brand name of Proteus®235

 

 

About INVAP

INVAP is an Argentinian company devoted to the design and construction of complex technological systems, with more than 40 years of history in the domestic market and more than twenty in the international scene. Its mission is to develop state-of-the-art technology in different industrial, scientific and applied research fields, thus creating "technological packages" with high added value, to meet domestic requirements or to be exported to international markets. www.invap.com.ar/en/

 

 

For further information, please contact:

 

IBA

 

Soumya Chandramouli

Chief Financial Officer

Bernard Dandoy

Investor Relations

+32 10 475 890

Investorrelations@iba-group.com

 

Thomas Ralet

Vice-President Corporate Communication

+32 10 475 890

communication@iba-group.com

 

For media and investor enquiries:

 

Consilium Strategic Communications

Amber Fennell, Matthew Neal, Ivar Milligan

+44 (0) 20 3709 5700

IBA@consilium-comms.com

 



additional treatment capacity



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: IBA SA, Chemin du Cyclotron 3, Louvain-la-Neuve 1348, Belgium
If you would like to unsubscribe and stop receiving these e-mails click here.